Genmab A/S (BMV:GMAB.N)
Mexico · Delayed Price · Currency is MXN | Market Cap | 656.47B +99.7% |
| Revenue (ttm) | 72.18B +22.3% |
| Net Income | 13.77B -37.9% |
| EPS | 232.21 -36.8% |
| Shares Out | n/a |
| PE Ratio | 35.68 |
| Forward PE | 36.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 222 |
| Open | 8,284.23 |
| Previous Close | n/a |
| Day's Range | 8,284.23 - 8,284.23 |
| 52-Week Range | 4,027.79 - 8,284.23 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Genmab price target raised to $57 from $42 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Genmab (GMAB) to $57 from $42 and keeps an Equal Weight rating on the shares.
Genmab price target raised to $80 from $58 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $80 from $58 and keeps a Buy rating on the shares.
Bicara Therapeutics price target lowered to $24 from $33 at Wedbush
Wedbush analyst David Nierengarten lowered the firm’s price target on Bicara Therapeutics (BCAX) to $24 from $33 and keeps an Outperform rating on the shares. Relevant to Bicara, Genmab’s (GMAB)…
Genmab price target raised to $70 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $70 from $50 and keeps a Buy rating on the shares. The company announced positive top-line results from the…
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the comp...
Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
(RTTNews) - Shares of several biotech companies moved higher following quarterly financial results, clinical trial developments and business updates. Genmab reported positive Phase 3 results for its c...
Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for Its Head and Neck Cancer Treatment
Genmab stock saw an over 30% rally on Wednesday following a clinical trial update for its head and neck cancer drug.
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
Genmab Transcript: Study result
Three phase III programs reported positive results across DLBCL, platinum-resistant ovarian and head and neck cancers. Petosemtamab colorectal data support further development, with potential launches beginning in 2027.
Genmab Press release: Study result
Genmab issued a press release on October 28, 2026, disclosing material business information to investors.
Genmab Slides: Study result
Genmab has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Genmab Shares Jump 16% as Rally Builds on Cancer Drug Wins, JPMorgan Upgrade and Head and Neck Trial Hopes
Genmab shares rose 16% after encouraging ovarian and colorectal cancer trial results, a JPMorgan upgrade and stronger expectations for its experimental drug pipeline.
Genmab announces results from Phase 3 LiGeR-HN1 trial of petosemtamab
Genmab (GMAB) announced topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor and ...
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigation...
Genmab Reaches Analyst Target Price
In recent trading, shares of Genmab A/S (Symbol: GMAB) have crossed above the average analyst 12-month target price of $43.85, changing hands for $44.69/share. When a stock reaches the target an analy...
Genmab price target raised to DKK 3,200 from DKK 2,850 at BofA
BofA raised the firm’s price target on Genmab (GMAB) to DKK 3,200 from DKK 2,850 and keeps a Buy rating on the shares.
Genmab price target raised to $52 from $43 at TD Cowen
TD Cowen analyst Yaron Werber raised the firm’s price target on Genmab (GMAB) to $52 from $43 and keeps a Buy rating on the shares. The firm said its strong…
Genmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck Cancer
(RTTNews) - Genmab (GMAB) reported updated Phase 2 results showing that Potesemtamab in combination with Pembrolizumab delivered encouraging survival and response rates in patients with first-line rec...
Genmab Shares Jump After Positive Cancer Study Results
The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.
Genmab announces updated Phase 2 data on petosemtamab
Genmab (GMAB) announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor and leucine-rich repeat...
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent...
Genmab upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Genmab (GMAB) to Overweight from Neutral with a price target of DKK 3,500, up from DKK 2,050, after the company’s ovarian cancer treatment Rina-S met its primary and…
Genmab's Petosemtamab Delivers Strong Response Rates In Metastatic Colorectal Cancer
(RTTNews) - Genmab (GMAB) reported updated Phase 2 data showing that Petosemtamab, when combined with standard chemotherapy, continued to demonstrate encouraging response rates in patients with metast...